Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Clinical Oncology: Case Reports
Paul J Davis Author
Subjects of specialization
Affiliation
molecular mechanisms, plasma membrane-initiated actions, ion transporters
Prof and Head of the American Board of Internal Medicine, USA
Biography
Dr. Davis directs a group of scientists who have defined molecular mechanisms for many nongenomic, plasma membrane-initiated actions of thyroid hormone, including actions on plasma membrane ion transporters, intracellular protein trafficking, phosphorylation of nuclear hormone receptors and of p53 and on transcription of specific genes. They have described the cell surface receptor for thyroid hormone on integrin avb3 and the actions of tetraiodothyroacetic acid (tetrac) and reformulated (nanoparticulate) tetrac initiated at this plasma membrane receptor that are anti-angiogenic and anti-cancer by multiple cell surface and intracellular pathways.
Publications
Conference Proceeding Open Access
Market Analysis of Biology, Immuno Oncology and Drug Discovery Conference
Author(s): Paul J Davis
The global cancer therapeutics market size was valued at $98,900 million in 2018 and is estimated to reach at $180,193 million by 2026, registering a CAGR of 7.7% from 2019 to 2026. Cancer therapeutics involves the use and administration of chemotherapy and oncology drugs to treat cancer.
Increase in cancer prevalence, surge in collaboration between pharmaceutical companies, and rise in cancer research are the key factors that augment the growth of the cancer therapeutics market. Furthermore, growth in geriatric population is expected to boost the market growth.
Social Media
Google Scholars / Researchers Sites
